Welcome to our dedicated page for Adc Therapeutics Sa news (Ticker: ADCT), a resource for investors and traders seeking the latest updates and insights on Adc Therapeutics Sa stock.
ADC Therapeutics SA reports news on its commercial-stage oncology business focused on antibody-drug conjugates. The company markets ZYNLONTA (loncastuximab tesirine-lpyl), a CD19-directed ADC with FDA accelerated approval and European Commission conditional approval for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.
Recurring updates cover ZYNLONTA product revenue, manufacturing and commercialization activity, clinical development in combination regimens and earlier lines of therapy, including LOTIS program studies, and corporate financing matters. Company news also includes quarterly financial results, investor presentations, conference participation and equity inducement grants under its compensation plans.
ADC Therapeutics (NYSE: ADCT) will host a conference call and live webcast on December 3, 2025 at 8:00 a.m. EST to provide an update on the LOTIS-7 Phase 1b open-label trial. The trial evaluates safety and efficacy of ZYNLONTA combined with bispecific antibody glofitamab (COLUMVI) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).
Participants can register to join by phone (toll-free 1-800-836-8184 for North America and Canada) or via a live webcast on the company's Investors "Events and Presentations" page at ir.adctherapeutics.com. The archived webcast will be available for 30 days after the call.
ADC Therapeutics (NYSE: ADCT) announced grants of options to purchase an aggregate of 47,000 common shares to two new employees on December 1, 2025 as inducements for employment. The Compensation Committee approved the grants under the company's Inducement Plan in reliance on the NYSE employment inducement exemption (Rule 303A.08).
The options vest 25% on the first anniversary and then 1/48th monthly thereafter, fully vesting on the fourth anniversary, subject to continued employment.
ADC Therapeutics (NYSE: ADCT) reported Q3 2025 results and operational updates on Nov 10, 2025. Key items: Q3 product revenue $15.8M and 9M revenue $51.2M; Q3 net loss $41.0M ($0.30/share) and 9M net loss $136.2M ($1.14/share). The company completed a $60M PIPE with estimated net proceeds of $57.6M, which would raise cash to ~$292.3M. Clinical updates: LOTIS-7 data expected by year-end 2025; LOTIS-5 topline expected in 1H 2026; Phase 2 IIT in follicular lymphoma shows ORR 98.2% and CR 83.6% with 12-month PFS 93.9% (median follow-up 28 months). IND-enabling work for PSMA ADC expected complete by end of 2025.
ADC Therapeutics (NYSE: ADCT) will host a conference call and live webcast on Monday, November 10, 2025 at 8:30 a.m. EST to report third quarter 2025 financial results and provide operational updates.
Participants can register in advance and join the call via the North America toll-free number 1-800-836-8184. A live webcast will be available under Events and Presentations in the Investors section at ir.adctherapeutics.com. It is recommended to join 10 minutes early. The archived webcast will remain available for 30 days after the call.
ADC Therapeutics (NYSE: ADCT) will present at three investor conferences in November 2025 with CEO Ameet Mallik participating in each session.
Schedule:
- Stephens Biotechnology Virtual Fireside Chats – Nov 3, 2025 at 12:00 p.m. ET (virtual; no replay or transcript)
- Guggenheim Second Annual Healthcare Innovation Conference – Nov 11, 2025 at 1:30 p.m. ET (Boston; live webcast available)
- Jefferies Global Healthcare Conference – Nov 19, 2025 at 12:30 p.m. GMT (London; live webcast available)
Live webcasts for Guggenheim and Jefferies will be available on the company’s Events & Presentations page at ir.adctherapeutics.com, and replays will be available for approximately 30 days after each event.
ADC Therapeutics (NYSE: ADCT) announced a $60.0 million PIPE financing on October 13, 2025, selling 11.3 million common shares at $4.00 each and pre-funded warrants to purchase 3.8 million shares at $3.90 each.
The PIPE is led by TCGX with participation from Redmile Group and others and is expected to close on October 27, 2025, subject to customary conditions. Net proceeds are estimated at $57.6 million after fees. The company reported Q3 2025 ZYNLONTA net product revenues of $15.8 million and $234.7 million cash on hand as of September 30, 2025, which would rise to approximately $292.3 million after the PIPE.
ADC Therapeutics (NYSE: ADCT) has granted stock options to four new employees as part of their employment inducement package. The grants, totaling options to purchase 162,000 common shares, were approved by the Company's Compensation Committee under the Inducement Plan.
The stock options will vest over a four-year period, with 25% vesting on the first anniversary and the remaining vesting monthly at 1/48th of the total shares, contingent on continued employment. The grants were made in compliance with NYSE's Listed Company Manual Rule 303A.08.
ADC Therapeutics (NYSE: ADCT) has announced equity compensation grants to two new employees as part of its employee inducement plan. The company granted options to purchase 29,700 common shares on September 2, 2025.
The grants were approved by the Compensation Committee under the Company's Inducement Plan and comply with NYSE's Listed Company Manual Rule 303A.08. The options will vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly thereafter, contingent on continued employment.
ADC Therapeutics (NYSE:ADCT), a commercial-stage leader in antibody drug conjugates (ADCs), announced its upcoming participation in the Cantor Global Healthcare Conference 2025. CEO Ameet Mallik will engage in a fireside chat on September 3, 2025, at 9:10 a.m. ET.
Investors can access the presentation through a webcast on the Events & Presentations page of ADC Therapeutics' investor relations website. The webcast recording will remain available for approximately 30 days after the event.
ADC Therapeutics (NYSE:ADCT) reported Q2 2025 financial results and operational updates, highlighting significant progress in their ZYNLONTA® clinical programs. The company's LOTIS-7 trial showed impressive results with 93.3% overall response rate and 86.7% complete response rate in combination with glofitamab for r/r DLBCL patients.
Key financial developments include a $100 million PIPE financing, extending cash runway into 2028, and Q2 2025 net product revenues of $18.1 million. The company reported a net loss of $56.6 million ($0.50 per share). A strategic restructuring plan was announced, reducing global workforce by 30% and discontinuing early development efforts in solid tumors to focus on ZYNLONTA.
The LOTIS-5 Phase 3 trial is expected to reach PFS events by end-2025, with potential sBLA submission in H1 2026. The company's cash position stands at $264.6 million as of June 30, 2025.